Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Research and development revenue	$ 692,929	$ 416,361	$ 2,090,541	$ 1,256,004
Costs and expenses:
Costs of research and development revenue	392,544	266,929	1,612,810	1,169,351
Provision for contract losses	0	112,433	0	187,388
Research and development	1,901,548	986,054	5,918,888	2,857,670
General and administrative	1,692,837	1,643,493	4,994,458	4,772,117
Foreign currency exchange loss (gain), net	30,002	(16,240)	76,080	26,317
Total costs and expenses	4,016,931	2,992,669	12,602,236	9,012,843
Loss from operations	(3,324,002)	(2,576,308)	(10,511,695)	(7,756,839)
Other income:
Interest income	3,202	76,809	49,772	391,779
Other income	1,605,532	0	1,605,532	0
Total other income	1,608,734	76,809	1,655,304	391,779
Net loss	$ (1,715,268)	$ (2,499,499)	$ (8,856,391)	$ (7,365,060)
Basic and diluted net loss per common share (in dollars per share)	$ (0.06)	$ (0.09)	$ (0.32)	$ (0.27)
Basic and diluted weighted-average common shares outstanding (in shares)	28,079,157	27,482,157	27,754,597	27,467,051